Incruse Ellipta 55 μg

Incruse Ellipta contains umeclidinium, a long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD. It blocks M3 muscarinic receptors in the airways, providing 24-hour bronchodilation with once-daily dosing. The Ellipta dry-powder inhaler is simple to use with just three steps: open, inhale, close. It includes a dose counter that counts down from 30.

How to Use Incruse Ellipta

Inhale one dose once daily at the same time each day. Open the device cover to prepare the dose, breathe out fully (away from the inhaler), then place the mouthpiece in your mouth and inhale steadily and deeply. Hold your breath for 3 to 4 seconds, then breathe out slowly. Close the cover after use.

Incruse Ellipta is a maintenance inhaler for daily use, it is not a rescue inhaler and will not relieve sudden breathlessness. Always have a fast-acting reliever inhaler available for acute symptoms. Rinse your mouth with water after each use to reduce the risk of oral dryness.

One inhalation (55 mcg umeclidinium) once daily. Do not exceed one inhalation per day.

Common Side Effects

Common side effects include:

• Nasopharyngitis (runny or blocked nose, sore throat)
• Upper respiratory tract infections
• Headache
• Cough
• Urinary tract infections

These are generally mild. As an anticholinergic inhaler, Incruse Ellipta can occasionally cause urinary retention (difficulty passing urine), particularly in men with an enlarged prostate. Tell your doctor if you notice difficulty urinating. Dry mouth is also a possible effect.

Not for acute bronchospasm. Use with caution in narrow-angle glaucoma, urinary retention, and prostatic hyperplasia. Not recommended for asthma.

Contraindicated in severe milk protein allergy (contains lactose) and known hypersensitivity to umeclidinium.